Check out which companies are making headlines before the bell:
Merck–The pharmaceutical giant is selling its U.S. consumer brands to Germany's Bayer in a $14.2 billion deal. The two companies also struck a separate deal to collaborate on cardiovascular disease treatments.
General Electric—French President Hollande said GE's bid for Alstom's energy business is insufficient. Alstom is still in the process of reviewing GE's $16.9 billion, while it has not yet issued a response to a rival bid from Germany's Siemens.
Emerson Electric–The manufacturing company fell one cent short of estimates with quarterly profit of 80 cents, excluding certain items, while revenue was slightly below consensus as well. Emerson does say that it is seeing business slowly improve, despite uneven demand in recent months.
Mosaic–The fertilizer producer missed estimates by five cents with first quarter profit of 54 cents per share, with revenue short as well. Mosaic's bottom line was impacted by lower prices for phosphate and potash.
International Flavors–The maker of food additives earned $1.30 per share for the first quarter, five cents above estimates, with revenue scoring a beat as well. International Flavors said its bottom line is being helped by its January acquisition of rival Aromor.
DirecTV–The satellite TV operator reported first quarter profit of $1.63 per share, excluding certain items, 13 cents above estimates, though revenue was slightly short of consensus.
Nu Skin–The health products company beat estimates by 11 cents with first quarter profit of $1.05 per share, with revenue beating analyst forecasts as well. The company said it is particularly encouraged by the results considering the business disruption it experienced in China, before reaching agreements to resolve outstanding issues regarding its sales and marketing.
AIG–The insurance giant earned $1.21 per share, excluding certain items, for the first quarter, 14 cents above estimates, while revenue fell short of consensus. The insurer saw a drop in premiums as well as increased disaster losses, compared to a year earlier.
AstraZeneca–The company won FDA approval for its new heart pill Epanova, a drug it acquired after buying drug maker Omthera last year. It also projected annual sales of $45 billion by 2023, compared to $25.7 billion in 2013.
Activision Blizzard–Activision plans to spend $500 million developing and promoting its science fiction video game "Destiny." CEO Bobby Kotick had mentioned the number last week at the Milken conference last week, but the company has now clarified the number to say it does include marketing and support costs.
Anadarko Petroleum–Anadarko reported first quarter profit of $1.26 per share, excluding certain items, 11 cents above estimates. Anadarko saw oil and gas production up 3.2 percent versus a year earlier.
Vornado Realty–Vornado beat estimates by four cents with funds from operations of $1.31 per share, while revenue was shy of estimates. The company's bottom line was hit by a writedown related to its stake in retailer Toys "R" Us.
Supervalu—Jana Partners has raised its stake in the supermarket operator to 11.6 percent from the prior 6.6 percent.
Credit Suisse–Credit Suisse is in talks with the U.S. government about settling its ongoing tax case for as much as $1.6 billion. The probe centers on allegations that the bank helped Americans evade U.S. taxes.
AthenaHealth–The stock is under pressure after Greenlight Capital's David Einhorn told the Sohn Investment Conference he was short the stock. Einhorn said the provider of electronic health care records was simply at the wrong price and could fall 80 percent from its recent peak.
Tenet Healthcare —Tenet reported a wider than expected loss of 28 cents per share, excluding certain items. The hospital operator did report stronger revenue, helped by its purchase of Vanguard Health Systems.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org